

Date: 27-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai - 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai - 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation by Sastasundar Healthbuddy Limited (“SHBL”), material subsidiary of the Company, regarding Outcome of its Board Meeting.

Dear Sir/ Madam,

Pursuant to regulation 30(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (“SEBI Listing Regulations”), it is hereby informed that the board of directors of the Sastasundar Healthbuddy Limited (“SHBL”), material subsidiary of the Health X Platform Limited (formerly Sastasundar Ventures Limited) (“Company” or “HealthX”) at its meeting held today has approved the execution of a Agreement (“Tripartite Agreement”) by SHBL with the Company, and Envision India Fund (“Envision”), a qualified institutional buyer, having registration number GB20025232, incorporated under the laws of Mauritius, having its registered office/office at 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261 Mauritius.

The Tripartite Agreement is being executed pursuant to a share purchase agreement dated 25.02.2026 (“SPA”), entered into between Envision, SHBL and Mitsubishi Corporation, a company incorporated under the laws of Japan and having its registered office at 3-1, Marunouchi 2-Chome, Chiyoda-Ku, Tokyo 100-8086, Japan (“Mitsubishi”), whereby Envision has agreed to acquire the entire shareholding of Mitsubishi in SHBL. It may be pertinent to note that the Company has already made a disclosure regarding the execution of an SPA by SHBL on 25.02.2026 to the stock exchanges.

The Tripartite Agreement contemplates the merger of SHBL with the Company such that the economic interest of Envision in the Company post-merger remains the same as it was in SHBL prior to the merger, subject to the same being in compliance with applicable laws. It is also agreed in the Tripartite Agreement that, if the merger cannot be consummated, SHBL shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. The Tripartite Agreement grants Envision the right to appoint a board observer in a non-voting capacity to the Board of SHBL and also grants Envision the right to appoint a director to the Board of SHBL in certain circumstances.

The Company received the aforesaid information from SHBL on February 27, 2026 at 2:04 PM. This is for your information and record.

Yours faithfully,
For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

HEALTH X PLATFORM LIMITED

(formerly known as Sastasundar Ventures Limited)

CIN: L65993WB1989PLC047002

Azimganj House, 2nd Floor, 7, Abanindra Nath Thakur Sarani, (Formerly Camac Street), Kolkata- 700 017
Tel: +91 33 2282 9330 | Email: info@sastasundar.com | Website: www.sastasundarventures.com